Intuitive Surgical’s Premium Rating Faces Its Sternest Test Yet
Published on 07/23/2026 at 19:32 | Redaktion boerse-global.de
The robotics pioneer that has dominated soft-tissue surgery for years is now navigating a perfect storm of competitive pressure, operational hiccups, and a market that has turned decidedly unforgiving. Intuitive Surgical’s shares slipped another 2.18 percent on Thursday to €292.35, inching ever closer to the 52-week low of €289.05 set just days earlier. The trigger: Johnson & Johnson’s Ottava surgical robot received FDA clearance, marking the first time a deep-pocketed rival will compete directly in Intuitive’s core market.
The new entrant is no me-too device. Ottava integrates its robotic arms directly into the operating table, a design that frees up as much as 50 percent more floor space compared with Intuitive’s traditional boom-and-cart systems. Johnson & Johnson is wasting no time, announcing an immediate commercial rollout at select US hospitals, with plans to expand quickly into Western Europe and Japan.
The competitive threat lands at a moment when Intuitive Surgical’s stock was already reeling. Year-to-date, the shares have tumbled roughly 35 percent — a figure that has since widened to 39.05 percent, according to the latest tally. The 200-day moving average now sits 30.08 percent above the current price, a gap that underscores just how dramatically sentiment has soured since January, when the stock touched an all-time high of $516.50.
Strong numbers, brutal reception
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
The selloff is particularly striking given the underlying financial performance. Intuitive Surgical reported second-quarter revenue of $2.89 billion, an 18.5 percent increase year-over-year, while adjusted earnings per share beat analyst estimates by nearly 12 percent. The adjusted operating margin climbed to 40.9 percent, up 2.1 percentage points from a year ago, and the company’s cash pile stands at a formidable $8.63 billion.
CEO Dave Rosa pointed to progress across the company’s portfolio, from the da Vinci and Ion platforms to expanding digital offerings. But the market fixated on the soft spots. Growth in da Vinci procedures in the US — the company’s most important market — slowed to 12 percent in the second quarter. Management attributed the deceleration to patients postponing so-called “benign” surgical procedures amid economic uncertainty, compounded by the expiration of enhanced tax credits under the Affordable Care Act, which has created insurance coverage gaps.
Adding to the unease, a Class II recall of certain da Vinci components has further weighed on operating volumes at large hospital systems. Insider selling over the past three months — totaling $3.1 million in shares — has done little to reassure investors, even if such sales are not necessarily a vote of no confidence.
Options market signals more pain ahead
The bearish sentiment extends into the derivatives market. The put-call ratio for contracts expiring at the end of August stands at 1.29, a clear signal that options traders are betting on further downside. The strike price of the most active puts sits at $317, implying a potential additional decline of roughly 7 percent from current levels.
On a technical basis, the stock is deeply oversold. The 14-day relative strength index has fallen to 29.4, below the threshold of 30 that analysts typically consider indicative of oversold conditions. Yet the pattern of lower highs and lower lows suggests that bargain hunters have so far been reluctant to step in.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Wall Street holds the line — for now
Despite the mounting headwinds, the analyst community has not abandoned its bullish stance. The consensus rating remains “Moderate Buy,” with an average price target near $509 — implying more than 70 percent upside from current levels. Several firms, including Bernstein and Stifel, trimmed their price targets after the earnings report but maintained positive ratings. The stock trades at a price-to-earnings multiple of 47.52, a premium that reflects the market’s long-standing belief in Intuitive’s moat, but one that now looks increasingly vulnerable to erosion.
The coming weeks will test whether that premium can hold. If the shares breach the $317 level — a threshold that options activity suggests is in play — it would signal that investors are fundamentally repricing the company’s growth prospects in a world where Intuitive Surgical is no longer the only game in town.
Ad
Intuitive Surgical Stock: New Analysis - 23 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
